Biomarker
This presentation is the property of its rightful owner.
Sponsored Links
1 / 34

BioMarker PowerPoint PPT Presentation


  • 92 Views
  • Uploaded on
  • Presentation posted in: General

BioMarker. Definition:. Biomarker is a substance used as an indicator of a biologic state Existence of living organisms or biological process. A particular disease state A fragment of DNA sequence. Proteins. Nucleic acids. Carbohydrate. Lipids. Small molecules. Biomarkers.

Download Presentation

BioMarker

An Image/Link below is provided (as is) to download presentation

Download Policy: Content on the Website is provided to you AS IS for your information and personal use and may not be sold / licensed / shared on other websites without getting consent from its author.While downloading, if for some reason you are not able to download a presentation, the publisher may have deleted the file from their server.


- - - - - - - - - - - - - - - - - - - - - - - - - - E N D - - - - - - - - - - - - - - - - - - - - - - - - - -

Presentation Transcript


Biomarker

BioMarker

Definition:

Biomarker is a substance used as an indicator of a biologic state

Existence of living organisms or biological process.

A particular disease state

A fragment of DNA sequence

Proteins

Nucleic acids

Carbohydrate

Lipids

Small molecules


Biomarkers

Biomarkers

Location of the biomarker:

Location of a particular molecule can also be a marker

Cellular-subcellular locations

Tissue or organ locations

Thymidylate synthase (TS)

nucleus vs the cytoplasm

The higher the level in NE, lower level in the cyto.

Lower survival in colorectal cancer patients

Galectin-3

Galectin-3 is a member of lectin family. It is wildly distributed

In tissue of epithelial, fibroblast, and dendritic cells.

Blood Galectin-3

Predict the outcomes for patients with symptoms of heart failure


Biomarker1

Biomarker

Detection of biomarker

Detection of biomarker – diagnosis

Self properties, e.g enzymatic activities

Antibodies, IHC, ELISA

Detection of biomarker

Quantitative

a link between quantity of the marker and disease

Qualitative

a link between exist of a marker and disease


Biomarker diagnosis

Ideal Marker for diagnosis

Biomarker & Diagnosis

Should have great sensitivity, specificity, and accuracy in reflecting total disease burden. A tumor marker should also be prognostic of outcome and predictive of tumor recurrence and effectiveness of anti-cancer treatments.

Biomarker for Screening

  • The marker must be highly specific, minimize false positive and negative

  • The marker must be able to clearly reflect the early stage of disease

  • The marker must be easily detected without complicated medical

  • procedures. The disease markers released to serum and urine are good

  • targets for application of early screening.

  • The method for screening should be cost effective.

Samples for biomarker detection

Blood, urine, or other body fluids samples

Tissue samples


Biomarker discovery and validation

Biomarker Discovery and Validation

Correlation: a biomarker vs a disease or status of a disease

Do not need understand functions

Detection: Detection of a particular marker is important

Validation: Build statistical correlation – large number of samples

Validation: sensitivity and specificity

Validation: Stand alone vs along with other markers


Common serum markers for cancer diagnosis prognosis

Common Serum Markers for Cancer Diagnosis/prognosis


Common biomarker for cancer

Common Biomarker for Cancer

AFP (>100 ng/ml)

Alpha fetoprotein (AFP) is typically found in the developing fetus. Because of the association of the rapid cell growth, this fetal protein is also used as a tumor marker. non cancerous liver diseases such as cirrhosis and viral hepatitis can lead to high level AFP

CEA (>10 ng/ml)

Carcinoembryonic antigen (CEA) is produced during fetal development. After birth, the production of CEA stops and is undetectable. CEA has also been found elevated in nonmalignant tumors such as pleural effusions. Elevation of CEA after conventional treatment of neoplasms has been correlated with a recurrence of cancer

CA19-9 (>37 U/ml)

Carbohydrate Antigen 19-9 (CA 19-9) is present in the fetus in the epithelium of the fetal stomach. It is primarily used as a marker for pancreatic cancer. High levels also exist in conditions such as non-malignant liver disease and other disorders of the gastrointestinal tract.


Common biomarker for cancer1

Common Biomarker for Cancer

hTG (>10 ng/ml)

Thyroglobulin (hTG) is a glycoprotein that is found in thyroid gland. This protein binds to thyroxine, which controls the rate of metabolic processes in body.

HCG (>10 mIU/ml)

Human Chorionic Gonadotropin-beta (HCG) is normally produced by the placenta during pregnancy, an indicator of pregnancy. The protein can be detected in serum or urine. Non-malignant elevations may be observed in pregnancy, ulcers, duke’s disease, and cirrhosis. Levels of HCG are useful in monitoring the effectiveness of treatment.

Ferr (>120 ng/ml)

Ferritin is an iron binding storage found in the liver, spleen, and bone marrow. Elevated levels observed in non-cancerous conditions include rheumatoid arthritis and anemia


Common biomarker for cancer2

Common Biomarker for Cancer

NSE (>12 ng/ml)

Neuron Specific Enolase (NSE) is produced by neurons and neuroendocrine cells of the central and peripheral nervous system.

b2M (high level)

Beta 2-Microglobulin, (B2M), is an 11 kD protein associated with the outer membrane of many cells including lymphocytes. It is the small subunit of the MHC class I molecule. B2M is present in small amounts in serum, csf, and urine of normal people. A non-malignant condition associated with high b2M levels is pancreatitis

a2M (<500 mg/ml)

Alpha 2 Macroglobulin (A2M) is a large protease inhibitor, 720 kD, capable of irreversibly binding and inhibiting a wide variety of proteases including plasmin, pepsin, trypsin, chymotrypsin, and cathepsin D.


Prostate cancer marker psa

Prostate Cancer marker PSA

PSA is a protein normally made in the prostate gland in ductal cells that make some of the semen. PSA helps to keep the semen liquid. PSA, also known as kallikrein III, seminin, semenogelase, γ-seminoprotein and P-30 antigen, is a glycoprotein, a serine protease

PSA has several forms in serum

Free

Pre-enzyme

Complex

Inactive


Prostate cancer diagnosis with psa

Prostate Cancer Diagnosis with PSA

Cancer of the prostate does not cause any symptoms until it is locally advanced or metastatic.

There is a correlation between elevated PSA and prostate cancer.

Diagnosis of PSA for prostate cancer in the most time means measure the PSA

In serum samples.

Detection of PSA allow early detection of prostate cancer.

Large screening trials have shown that PSA nearly doubles the rate of detection possible by combine with other methods. Based on these data, PSA testing was approved by the US FDA for the screening and early detection of prostate cancer.

PSA is also found in the cytoplasm of benign prostate cells.

Separately measure different forms of PSA give better results


Prostate marker psma

Prostate-specificmembraneantigen (PSMA) is a type 2 integral membrane glycoprotein. PSMA possesses glutamate carboxypeptidase activity, Detectable levels of PSMA are also found in small intestine and brain. Intestinal PSMA may play a role in the metabolism of dietary-glutamated folate derivatives. Brain PSMA, also referred to N-acetylated -linked acidic dipeptidase (NAALADase), may modulate glutamatergic neurotransmission

Prostate Marker PSMA

In addition to being abundantly and preferentially expressed on the surface of prostate cancer cells, PSMA is also present on endothelial cells of new blood vessels

PSMA also expressed in brush border of proximal tubules of normal kidneys and tissue samples from both benign and malignant renal lesions (neovasculature)

The role of PSMA as a cancer marker is still under

investigation. PSMA is sensitive to reflect prostate cancer. The specificity, however, is not fully verified. Most use is image the prostate metastasis by radio-isotopes


Prostate marker psma1

Prostate Marker PSMA

The role of enzymatic activity (folate hydrolase) of PSMA in cellular transformation and metastasis is not understood.

PSMA has isoforms produced by alternative splicing.

In normal prostate epithelia, PSMA is expressed primarily as a cytoplasmic protein termed PSM'

In prostate carcinomas, however, differential mRNA splicing leads to expression of PSMA as a type 2 integral membrane glycoprotein possessing a 19-aa cytoplasmic fragment, a single 24-aa membrane-spanning domain, and a 707-aa extracellular region

Unlike PSA, PSMA is not a secret protein. Serum level is very low even elevated. PSMA is membrane protein, ideal for targeting


Ovarian cancer diagnosis by ca 125

Ovarian Cancer Diagnosis by CA-125

CA-125, a product of the MUC16 gene, is a mucin made by certain cells in the body which include those of the uterine tubes, uterus, cervix, and the lining of the abdominal and chest cavities

CA125 is a membrane glycoprotein that has very short cytoplasmic domain

and a very long extracellular domain. The cellular function of the protein is

still unknown. The protein exist in the cells of normal and cancerous tissues of ovarian.

The release of proteolytic fragments of CA125 leads to elevation of CA125 level in bloodstream, which is associated with progression of ovarian cancer and a few other cancer types. The CA125 level can be over 10 folds higher in ovarian cancer patients compared to the level in normal.

Diagnosis of ovarian cancer is often simple. A pelvic mass is suspicious and

is very often associated with ovarian cancer. However, when the pelvic mass is detected, the ovarian cancer usually has already advanced to quit advanced stage. There is no symptom for ovarian cancer, especially during

early stage.


Her 2 neu

Her-2/neu

The HER (erbB) family member are

Growth factor receptors.

In the HER (erbB) family, only Her-2

did not have identified ligand.

Expression level correlates with growth

of breast cancer cells.

Diagnostic/prognostic applications.

HER2-positive metastatic breast cancer have a more aggressive disease, greater likelihood of recurrence, poorer prognosis and decreased survival.


Beta 2 microglobulin b2m

Beta-2-microglobulin (b2M)

B2M is the small subunit of the MHC class I molecule.

How does the protein promotes tumor growth and metastasis – the expression of MHC class 1 in many tumor cells are repressed.

An hypothesis is that b2M is a signaling molecule that linked to cell growth and survival pathway.

What are the target of the signal? Receptors?

Known or unknown pathway?


Biomarker targeted imaging

Biomarker & Targeted Imaging

Imaging probe link to a targeting moiety that target to bio-marker

Basic requirement: the marker must presented on cell surface in high number

Ideally:

Theinteraction between marker and targeting moiety is strong

The interaction is highly specific

The target internalization – high payload

Distribution at neovasculature, minimal tissue penetration


Imaging targeting psma

Imaging Targeting PSMA

Antibody is targeting moiety

Antibody conjugated quantum dots

Antibody


Imaging targeting psma1

Imaging Targeting PSMA

Antibody conjugated to radio-labels

Patient Images

No resolution – hardly tissue image

High sensitivity – good for detecting metastasis


Mr image target her 2

MR Image Target Her-2

Advantage for both

Her-2 and PSMA imaging is that the high number and distribution of the marker in agiogenesis tissue

Disadvantage for both

Her-2 and PSMA imaging is that the ligand for Her-2 and PSMA are not identified. Antibodies are the only choice

The levels of both Her-2 and PSMA correlate well with aggressiveness of disease


Therapies target biomarkers

Therapies Target Biomarkers

Simply target the biomarker by antibody

Therapeutic agent link to a targeting moiety that target to bio-marker

Basic requirement: the marker must presented on cell surface

Ideally:

The interaction is highly specific.

The target internalization, accumulation good # of agent.

Distribution at neovasculature, minimal tissue penetration.

The level of marker correlate with disease progression


Therapy target her 2

Therapy Target Her-2

Herceptin

Herceptin binds to HER2-positive cancer cells and may block them from dividing and growing.

Herceptin attaches to the HER2-positive cancer cells and may signal the body's immune system to destroy the cell.

Herceptin can also conjugated with chemotherapy (paclitaxel) to destroy HER2-positive cancer cells.


Herceptin

Herceptin

100%

33%

10%

Mouse

Fused

Humanized


Mechanism of herceptin

Mechanism of Herceptin


Molecular mechanism for her 2 antibody

Molecular Mechanism for Her-2 Antibody


Therapy target her 21

Therapy Target Her-2

Small Molecules target HER-2

erlotinib (Tarceva), a kinase inhibitor for EGFR/HER1

Target HER-2

Affibody target HER-2

Polypeptides of 58 aa derived from IgG binding domain

of protein A, forming a three-helix bundle.


Therapy target psma

Therapy Target PSMA

One important advantage is the quick

endocytosis of the PSMA upon the

antibody binding.

Due to main neovascular distribution,

targeting of PSMA is very easy, less tissue penetration.

Both Her-2 and PSMA have a good

property is their high level correlate well with aggressiveness of disease.


Compounds target psma

Compounds Target PSMA


Psma target for tumor blood vessel

PSMA Target for Tumor Blood Vessel

PSMA is found highly expressed in neovascular of many cancer types,

especially the new vessel in cancer mass.

PSMA is an excellent target for delivery to many cancer


Cancer in stem cells or progenitor cells

Cancer in Stem Cells or Progenitor Cells


Cancer stem cell target

Cancer Stem Cell Target


Drugs target cancer stem cells

Drugs Target Cancer Stem Cells


Imaging and therapeutic agent

Imaging and Therapeutic Agent

The most significance of the double agent is the immediately follow the effectiveness

of treatment. Also follow whether the therapies have been targeted to the sites


Diagnosis by proteomic

Diagnosis by Proteomic

No single marker can accurately reflecting a disease. Not even a panel of markers.

We need analyses a large number of disease markers.


  • Login